CompletedNot Applicable

Probiotics and Multi-Drug Resistant Urinary Tract Infection

United States25 participantsStarted 2018-07-05

Plain-language summary

This pilot study is a single-site randomized, double blinded placebo-controlled in females with recurrent multi-drug resistant (MDR) urinary tract infections(UTI). Our study hypothesizes that a novel probiotic strain improves antibiotic sensitivity patterns in these former MDR UTIs.

Who can participate

Age range18 Years – 90 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female, age 18-90 * Ability to void spontaneously * Suffers from recurrent multi-drug resistant or extensively drug resistant urinary tract infections caused by E.coli, Klebsiella, Enterococcus, Citrobacter, Proteus, Enterobacter, Serratia and Providencia. Exclusion Criteria: * Has staghorn renal calculi, chronic hydronephrosis, intermittent catherization, indwelling urinary catheters, urinary diversions, end stage renal disease on hemodialysis, transplantation, HIV, cirrhosis, pancreatitis, allergy to soy or milk/milk proteins or lactose intolerance * Pregnant or breastfeeding * Currently taking probiotics. 4 week washout.

What they're measuring

Change in Resistance Pattern

Timeframe: 6-8 weeks after initial dose

Bacterial isolate genomic characteristics

Timeframe: 12 months after initial dose

Trial details

NCT IDNCT03644966

SponsorOchsner Health System

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-15

View on ClinicalTrials.gov More Urinary Tract Infections trials